A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
复制标题
DOI：
10.1016/j.cell.2022.01.012
复制
发表时间：
2022-03-03
期刊：
影响因子：
64.5
通讯作者：
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium
中科院分区：
文献类型：
--
作者：
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk;COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium
严重的Covid-19的治疗目前受到临床异质性和特定免疫生物标志物的不完整描述的限制。我们在这里为与流感和败血症患者的综合比较与健康志愿者的综合比较中的患者提供了一个全面的多摩变血集。我们确定免疫特征和宿主反应的相关性。疾病严重程度的标志涉及细胞，其炎症介质和网络，包括祖细胞以及特定的髓样和淋巴细胞亚群，免疫库的特征，急性相反应，代谢和凝结。涉及AP-1/p38mapk的持续性免疫激活是Covid-19的特定特征。等离子体蛋白质组将亚表型化为患者簇，可预测严重程度和结果。基于系统的集成分析，包括各种方式的张量和基质分解，揭示了与流感和败血症相比，与严重性和特异性相关的特征组。我们的方法和血液地图集将支持未来的药物开发，临床试验设计以及Covid-19的个性化医学方法。
血液图集描述了COVID-19中的先天和适应性免疫失调
Covid-19，流感和所有引起败血症的共享和特定的免疫特征
多运动免疫分析可区分Covid-19中住院的患者严重程度
免疫激活和增殖涉及与Covid-19相关的AP-1/p38mapk
与从败血症或流感患者获得的样品相比，对患者血液样本的多摩卡分析揭示了Covid-19的相似性和特定特征，这可能会为严重的Covid-19提供更好的靶向疗法。
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism, and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems-based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design, and personalized medicine approaches for COVID-19. Blood atlas delineating innate and adaptive immune dysregulation in COVID-19 Shared and specific immune signatures of COVID-19, influenza and all cause sepsis Multi-omic immune profiling differentiates hospitalized patient severity in COVID-19 Immune activation and proliferation involving AP-1/p38MAPK associated with COVID-19 A multi-omic analysis of patient blood samples reveals both similarities and specific features of COVID-19 when compared with samples obtained from sepsis or influenza patients, which could yield better targeted therapies for severe COVID-19.
登录
查看更多内容
影响因子：
48
作者：
Amezquita, Robert A.;Lun, Aaron T. L.;Hicks, Stephanie C.
通讯作者：
Hicks, Stephanie C.
影响因子：
100.3
作者：
Chen, Zeyu;John Wherry, E.
通讯作者：
John Wherry, E.
DOI：
10.1126/science.abc6261
发表时间：
2020-09-04
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Arunachalam PS;Wimmers F;Mok CKP;Perera RAPM;Scott M;Hagan T;Sigal N;Feng Y;Bristow L;Tak-Yin Tsang O;Wagh D;Coller J;Pellegrini KL;Kazmin D;Alaaeddine G;Leung WS;Chan JMC;Chik TSH;Choi CYC;Huerta C;Paine McCullough M;Lv H;Anderson E;Edupuganti S;Upadhyay AA;Bosinger SE;Maecker HT;Khatri P;Rouphael N;Peiris M;Pulendran B
通讯作者：
Pulendran B
影响因子：
8.8
作者：
De Mattos-Arruda, Leticia;Sammut, Stephen-John;Caldas, Carlos
通讯作者：
Caldas, Carlos
影响因子：
7.3
作者：
Diao, Bo;Wang, Chenhui;Chen, Yongwen
通讯作者：
Chen, Yongwen